Gamma-aminobutyric acid type A receptor alpha-4 beta-3 delta subunit complex (GABAAR α4β3δ)

The Gamma-aminobutyric acid type A (GABA_A) receptor alpha-4 beta-3 delta (α4β3δ) is a heteropentameric ligand-gated ion channel primarily located at extrasynaptic and perisynaptic sites in the central nervous system [1, 5]. This specific receptor subtype is a key mediator of tonic inhibition, providing a persistent inhibitory chloride current that regulates the baseline excitability of neurons, particularly in the hippocampus and thalamus [2, 8]. Unlike synaptic GABA_A receptors containing the gamma-2 subunit, the α4β3δ isoform exhibits high affinity for GABA, slow desensitization, and a distinct pharmacological profile characterized by insensitivity to benzodiazepines and high sensitivity to neurosteroids [1, 7]. It plays a critical role in the pathophysiology of conditions such as postpartum depression, catamenial epilepsy, and premenstrual dysphoric disorder, where fluctuations in endogenous neurosteroids like allopregnanolone affect receptor expression and function [1, 9]. Therapeutic agents such as brexanolone and zuranolone act as positive allosteric modulators of this receptor to alleviate depressive symptoms by enhancing GABAergic tone [3, 9]. Additionally, the receptor is a target for the hypnotic agent gaboxadol and is highly sensitive to the effects of ethanol [5, 8]. Dysregulation of this receptor complex is also linked to anxiety disorders and changes in cognitive function during puberty [1, 2]. Overall, the α4β3δ receptor represents a specialized inhibitory component of the brain's signaling architecture with significant therapeutic potential in neuropsychiatry [12, 14].

Other names

alpha4beta3delta GABA-A receptorGABRA4-GABRB3-GABRD receptorExtrasynaptic GABA-A receptorNeurosteroid-sensitive GABA-A receptor

Positive allosteric modulation of the GABA_A receptor chloride channel, which enhances the inhibitory effect of GABA by increasing channel opening frequency and duration [7, 10]. Certain ligands, such as gaboxadol, act as direct agonists at the GABA binding site of this specific subunit configuration [4, 8].